FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944372010> ?p ?o ?g. }

• W2944372010 endingPage "635" @default.
• W2944372010 startingPage "626" @default.
• W2944372010 abstract "The objective of this trial, Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART), was to provide support and guidance for an evidence-based approach for the selection and monitoring of initial pharmacotherapy in patients with autism by assessing predictors of efficacy, tolerability, and safety. This randomized double-blind parallel-group study was conducted in three academic medical centers and a single private pediatric practice. Eighty children or adolescents (aged 6–17 yrs) with autistic disorder were enrolled, and 61 patients were randomized to the study drug. Of those patients, 51 completed the 10-week trial, and 31 completed an optional 12-week blinded extension phase. All patients were treated with 2 weeks of placebo before random assignment to receive aripiprazole (31 patients) or risperidone (30 patients) for 10 weeks. Sixteen placebo responders (20%) were excluded from further analysis. Drug dosing followed U.S. Food and Drug Administration (FDA) labeling, and weekly dosage adjustments were allowed until week 4; patients were then maintained on a fixed dose for 6 additional weeks. Safety, physical, and psychological assessments were recorded weekly or every 2 weeks. No significant differences in severity of illness between the aripiprazole and risperidone groups were noted at baseline. All patients significantly improved on the Aberrant Behavior Checklist-Irritability subscale after 1 week and continued for the remaining 9 weeks and the extension phase. Improvement was greatest in the risperidone group at every assessment period and was statistically significantly better than that in the aripiprazole group at weeks 3 and 6 (p<0.05). No dose-limiting adverse events occurred during the dose-titration period. Mean weight gain in the aripiprazole group was significantly less than that in the risperidone group at week 4 (0.62 vs 1.38 kg, p=0.033) and week 10 (1.61 vs 3.31 kg, p<0.001), but the difference became nonsignificant for the 31 patients completing the 3-month extension phase (4.36 vs 5.55 kg, p=0.26). Pharmacotherapy of patients with autism spectrum disorder resulted in behavioral improvement within 1 week and lasted at least 22 weeks. Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial. Our trial supports previous results of drug efficacy and safety in patients with autism spectrum disorder from other trials and extends the evidence-based support for choosing an FDA-approved drug for initial pharmacotherapy for autism spectrum disorder." @default.
• W2944372010 created "2019-05-16" @default.
• W2944372010 creator A5003936338 @default.
• W2944372010 creator A5005119541 @default.
• W2944372010 creator A5008497712 @default.
• W2944372010 creator A5013118838 @default.
• W2944372010 creator A5015604627 @default.
• W2944372010 creator A5015846526 @default.
• W2944372010 creator A5028309037 @default.
• W2944372010 creator A5032025013 @default.
• W2944372010 creator A5035964222 @default.
• W2944372010 creator A5037231847 @default.
• W2944372010 creator A5039251128 @default.
• W2944372010 creator A5050517525 @default.
• W2944372010 creator A5059041300 @default.
• W2944372010 creator A5068034195 @default.
• W2944372010 creator A5079740756 @default.
• W2944372010 creator A5082656806 @default.
• W2944372010 creator A5083496829 @default.
• W2944372010 creator A5087595155 @default.
• W2944372010 date "2019-05-29" @default.
• W2944372010 modified "2023-10-10" @default.
• W2944372010 title "Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized <scp>BAART</scp> Clinical Trial" @default.
• W2944372010 cites W1758325167 @default.
• W2944372010 cites W183484377 @default.
• W2944372010 cites W1968430210 @default.
• W2944372010 cites W1969516074 @default.
• W2944372010 cites W2000624544 @default.
• W2944372010 cites W2007445647 @default.
• W2944372010 cites W2018998808 @default.
• W2944372010 cites W2037835401 @default.
• W2944372010 cites W2096202887 @default.
• W2944372010 cites W2116795013 @default.
• W2944372010 cites W2121150539 @default.
• W2944372010 cites W2123247267 @default.
• W2944372010 cites W2130514663 @default.
• W2944372010 cites W2141464904 @default.
• W2944372010 cites W2160438215 @default.
• W2944372010 cites W2614349964 @default.
• W2944372010 doi "https://doi.org/10.1002/phar.2271" @default.
• W2944372010 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6555676" @default.
• W2944372010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31063671" @default.
• W2944372010 hasPublicationYear "2019" @default.
• W2944372010 type Work @default.
• W2944372010 sameAs 2944372010 @default.
• W2944372010 citedByCount "25" @default.
• W2944372010 countsByYear W29443720102019 @default.
• W2944372010 countsByYear W29443720102020 @default.
• W2944372010 countsByYear W29443720102021 @default.
• W2944372010 countsByYear W29443720102022 @default.
• W2944372010 countsByYear W29443720102023 @default.
• W2944372010 crossrefType "journal-article" @default.
• W2944372010 hasAuthorship W2944372010A5003936338 @default.
• W2944372010 hasAuthorship W2944372010A5005119541 @default.
• W2944372010 hasAuthorship W2944372010A5008497712 @default.
• W2944372010 hasAuthorship W2944372010A5013118838 @default.
• W2944372010 hasAuthorship W2944372010A5015604627 @default.
• W2944372010 hasAuthorship W2944372010A5015846526 @default.
• W2944372010 hasAuthorship W2944372010A5028309037 @default.
• W2944372010 hasAuthorship W2944372010A5032025013 @default.
• W2944372010 hasAuthorship W2944372010A5035964222 @default.
• W2944372010 hasAuthorship W2944372010A5037231847 @default.
• W2944372010 hasAuthorship W2944372010A5039251128 @default.
• W2944372010 hasAuthorship W2944372010A5050517525 @default.
• W2944372010 hasAuthorship W2944372010A5059041300 @default.
• W2944372010 hasAuthorship W2944372010A5068034195 @default.
• W2944372010 hasAuthorship W2944372010A5079740756 @default.
• W2944372010 hasAuthorship W2944372010A5082656806 @default.
• W2944372010 hasAuthorship W2944372010A5083496829 @default.
• W2944372010 hasAuthorship W2944372010A5087595155 @default.
• W2944372010 hasBestOaLocation W29443720101 @default.
• W2944372010 hasConcept C118552586 @default.
• W2944372010 hasConcept C126322002 @default.
• W2944372010 hasConcept C142724271 @default.
• W2944372010 hasConcept C168563851 @default.
• W2944372010 hasConcept C1862650 @default.
• W2944372010 hasConcept C187212893 @default.
• W2944372010 hasConcept C197934379 @default.
• W2944372010 hasConcept C204787440 @default.
• W2944372010 hasConcept C205778803 @default.
• W2944372010 hasConcept C27081682 @default.
• W2944372010 hasConcept C2776412080 @default.
• W2944372010 hasConcept C2777288759 @default.
• W2944372010 hasConcept C2778375690 @default.
• W2944372010 hasConcept C2778562196 @default.
• W2944372010 hasConcept C2780057945 @default.
• W2944372010 hasConcept C2780211496 @default.
• W2944372010 hasConcept C2780820931 @default.
• W2944372010 hasConcept C500440147 @default.
• W2944372010 hasConcept C71924100 @default.
• W2944372010 hasConceptScore W2944372010C118552586 @default.
• W2944372010 hasConceptScore W2944372010C126322002 @default.
• W2944372010 hasConceptScore W2944372010C142724271 @default.
• W2944372010 hasConceptScore W2944372010C168563851 @default.
• W2944372010 hasConceptScore W2944372010C1862650 @default.
• W2944372010 hasConceptScore W2944372010C187212893 @default.
• W2944372010 hasConceptScore W2944372010C197934379 @default.
• W2944372010 hasConceptScore W2944372010C204787440 @default.

• next